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Background: Creatine monohydrate (CrM) has been consistently reported to increase muscle creatine content and
improve high-intensity exercise capacity. However, a number of different forms of creatine have been purported to
be more efficacious than CrM. The purpose of this study was to determine if a buffered creatine monohydrate (KA)
that has been purported to promote greater creatine retention and training adaptations with fewer side effects at
lower doses is more efficacious than CrM supplementation in resistance-trained individuals.
Methods: In a double-blind manner, 36 resistance-trained participants (20.2 ± 2 years, 181 ± 7 cm, 82.1 ± 12 kg, and
14.7 ± 5% body fat) were randomly assigned to supplement their diet with CrM (CreapureW AlzChem AG, Trostberg,
Germany) at normal loading (4 x 5 g/d for 7-days) and maintenance (5 g/d for 21-days) doses; KA (Kre-AlkalynW, All
American Pharmaceutical, Billings, MT, USA) at manufacturer’s recommended doses (KA-L, 1.5 g/d for 28-days); or, KA
with equivalent loading (4 x 5 g/d for 7-days) and maintenance (5 g/d) doses of CrM (KA-H). Participants were
asked to maintain their current training programs and record all workouts. Muscle biopsies from the vastus lateralis,
fasting blood samples, body weight, DEXA determined body composition, and Wingate Anaerobic Capacity (WAC)
tests were performed at 0, 7, and 28-days while 1RM strength tests were performed at 0 and 28-days. Data were
analyzed by a repeated measures multivariate analysis of variance (MANOVA) and are presented as mean ± SD
changes from baseline after 7 and 28-days, respectively.
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Results: Muscle free creatine content obtained in a subgroup of 25 participants increased in all groups over time
(1.4 ± 20.7 and 11.9 ± 24.0 mmol/kg DW, p = 0.03) after 7 and 28-days, respectively, with no significant differences
among groups (KA-L −7.9 ± 22.3, 4.7 ± 27.0; KA-H 1.0 ± 12.8, 9.1 ± 23.2; CrM 11.3 ± 23.9, 22.3 ± 21.0 mmol/kg DW,
p = 0.46). However, while no overall group differences were observed (p = 0.14), pairwise comparison between the
KA-L and CrM groups revealed that changes in muscle creatine content tended to be greater in the CrM group
(KA-L −1.1 ± 4.3, CrM 11.2 ± 4.3 mmol/kg DW, p = 0.053 [mean ± SEM]). Although some significant time effects were
observed, no significant group x time interactions (p > 0.05) were observed in changes in body mass, fat free mass,
fat mass, percent body fat, or total body water; bench press and leg press 1RM strength; WAC mean power, peak
power, or total work; serum blood lipids, markers of catabolism and bone status, and serum electrolyte status; or,
whole blood makers of lymphocytes and red cells. Serum creatinine levels increased in all groups (p < 0.001) with
higher doses of creatine promoting greater increases in serum creatinine (p = 0.03) but the increases observed (0.1
– 0.2 mg/dl) were well within normal values for active individuals (i.e., <1.28 ± 0.2 mg/dl). Serum LDL was decreased
to a greater degree following ingesting loading doses in the CrM group but returned to baseline during the
maintenance phase. No side effects were reported.
Conclusions: Neither manufacturers recommended doses of KA (1.5 g/d) or KA with equivalent loading (20 g/d for
7-days) and maintenance doses (5 g/d for 21-days) of CrM promoted greater changes in muscle creatine content,
body composition, strength, or anaerobic capacity than CrM (20 g/d for 7-days, 5 g/d for 21-days). There was no
evidence that supplementing the diet with a buffered form of creatine resulted in fewer side effects than CrM.
These findings do not support claims that consuming a buffered form of creatine is a more efficacious and/or safer
form of creatine to consume than creatine monohydrate.
Keywords: Creatine monohydrate, Kre-Alkalyn, Training adaptations, Health, SafetyBackground
Creatine has proven to be one of the most effective and
popular dietary supplements for resistance-trained ath-
letes [1-3]. The form of creatine that has been most ex-
tensively studied has been creatine monohydrate (CrM)
[1]. Studies have consistently indicated that creatine sup-
plementation increases muscle creatine and phospho-
creatine concentrations by approximately 15-40%,
enhances anaerobic exercise capacity, and increases
training volume leading to greater gains in strength,
power, and muscle mass [1-10]. A number of potential
therapeutic benefits have also been suggested in various
clinical populations [11-17]. Studies have indicated that
creatine monohydrate is not degraded during normal di-
gestion and that nearly 99% of orally ingested creatine is
either taken up by tissues or excreted in urine [18-20].
Further, no medically significant side effects have been
reported in the literature [21-27]. Nevertheless, supple-
ment manufacturers have continually introduced newer
forms of creatine into the marketplace [1]. These newer
forms have been purported to have better physical and
chemical properties, bioavailability, efficacy, and/or
safety profiles than creatine monohydrate [1]. However,
there is little to no evidence that any of the newer forms
of creatine are more effective and/or a safer form of cre-
atine than CrM whether ingested alone and/or in com-
bination with other nutrients [1]. In addition, whereas
the safety, efficacy, and regulatory status of CrM is
clearly defined in almost all global markets; the safety,efficacy and regulatory status of other forms of creatine
present in today’s marketplace as a dietary or food sup-
plement is less clear [1].
A buffered form of creatine (Kre-AlkalynW [KA], All
American Pharmaceutical, Billings, MT, USA) has been
marketed as a more efficacious and safer form of creat-
ine than creatine monohydrate [28]. According to the
manufacturer’s website [28], this patented form of creat-
ine [29] is a “buffered” or “pH-correct” form of creatine
that remains more stable in the stomach, is not degraded
to creatinine, and thereby has greater bioavailability.
According to patent filings [29], this is accomplished by
adding an alkaline powder (e.g., soda ash, magnesium
glycerol phosphate, bicarbonate) to creatine (e.g., creat-
ine monohydrate, creatine phosphate, creatine pyruvate,
creatine citrate) in order to adjust the pH to a range be-
tween 7–14. The manufacturer claims that this form of
creatine is “the only Creatine guaranteed to stay 100%
stable all the way to the muscle cell”; that it is “up to ten
times more powerful than ordinary Creatine”; that “1.5
grams of Kre-Alkalyn is equivalent to about 10–15 grams
of ordinary Creatine”; that it is “an alternative to all the
bloating, cramping, and other side effects associated with
traditional creatine supplementation”; and, that it is “the
world’s most potent creatine” [28]. The manufacturer
cites several clinical studies on their website performed
in Bulgaria to support their claims [28,30]. However, we
could find no peer-reviewed articles cited in the National
Library of Medicine’s PubMed related to “Kre-Alkalyn”,
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or anyone else. One paper that was presented at the
International Society of Sports Nutrition annual meeting
in 2007 reported that the conversion of creatine to cre-
atinine from CrM at a pH of 1.0 and 37°C was less than
1% after 5, 30 and 120 minutes while KA had a 35%
greater conversion to creatinine under similar conditions
[31]. However, full details of this study have yet to be
published.
Our research group has extensive experience in con-
ducting clinical research studies on the efficacy and
safety of supplementing the diet during training with
various forms of creatine [9,25,26,32-39]. As a result,
AlzChem AG (Trostberg, Germany), a primary raw ma-
terial provider of pure creatine monohydrate, provided a
grant to our university to conduct an independent re-
search study to compare the effects of supplementing
the diet with KA at recommended doses (1.5 g/d for 28-
days) and creatine equivalent loading (20 g/d for 7-days)
and maintenance doses (5 g/d for 21-days) of KA to
CrM (20 g/d for 7-days, 5 g/d for 21-days) on muscle
creatine retention, body composition, strength, anaer-
obic capacity and markers of health status. We also
sought to determine whether ingesting the purported
buffered form of creatine would be associated with fewer
side effects than creatine monohydrate as claimed. The-
oretically, if KA is indeed a more efficacious form of cre-
atine, the recommended doses of KA (1.5 g/d) would be
as effective or more effective than consuming standard
loading (20 g/d for 7-day) and maintenance doses (5 g/d
for 21-days) of CrM on increasing muscle creatine levels
and training adaptations with fewer side effects. Add-
itionally, ingesting creatine equivalent loading and main-
tenance doses of KA would theoretically promote
greater effects with fewer side effects in those ingesting
standard loading and maintenance doses of CrM.
Methods
Experimental design
Table 1 presents the general experimental design
employed in this study. The study was conducted in a
double-blind, randomized controlled manner. The inde-
pendent variable was the type of creatine ingested.
Dependent variables included muscle creatine content,
body composition, one repetition maximum (1RM)
bench press and leg press, anaerobic sprint performance
capacity, serum and whole blood clinical markers of
health, and self-reported side effects. Dietary intake was
not controlled but participant’s dietary intake was
recorded prior to each testing session and analyzed for
energy intake and macronutrient content. Participants
were instructed to maintain their normal resistance-
training program and maintain training logs so training
volume could be compared. Subjects who qualified forthe study participated in a familiarization session in
which the study was explained to the participants and
informed consent was obtained. After the familiarization
session, subjects were matched for bodyweight, years of
training experience, and age and randomly assigned to
one of three groups: 1.) KA at manufacturer’s recom-
mended doses (KA-L, 1.5 g/d for 28-days); 2.) KA at cre-
atine equivalent loading (4 x 5 g/d for 7-days) and
maintenance (5 g/d for 21-days) doses as CrM (KA-H);
or, 3.) CrM at normal loading (4 x 5 g/d for 7-days) and
maintenance doses (5 g/d for 21-days).
Participants
Apparently healthy resistance-trained males with no self-
reported recent history of creatine supplementation were
recruited to participate in this study. Participants were
not allowed to participate in this study if they had any
metabolic disorder including known electrolyte abnor-
malities; heart disease, arrhythmias, diabetes, thyroid
disease, or hypogonadism; a history of hypertension,
hepatorenal, musculoskeletal, autoimmune, or neurologic
disease; if they were taking thyroid, anti-hyperlipidemic,
hypoglycemic, anti-hypertensive, anti-inflammatory, or
androgenic medications; or, if they had taken dietary sup-
plements containing creatine within three months prior
to the start of the study. Participants were recruited from
the student population and from area fitness facilities.
Participants completed demographic, health history and
exercise history forms. Those who met eligibility criteria
were informed of the requirements of the study and
signed informed consent statements in compliance with
the Human Subjects Guidelines of Texas A&M Univer-
sity and the American College of Sports Medicine. Sub-
jects participated in a familiarization session that
included practicing the Wingate anaerobic capacity test.
Testing sessions
Participants were instructed to record all food ingestion
on food record forms four days (4-d) prior to the start of
the study. In addition, subjects were asked to fast for
8 hours and abstain from exercise for 48 hours prior to
baseline testing. Once reporting to the lab, subjects
donated a muscle biopsy and fasting blood samples
using standard clinical procedures. Subjects were then
weighed, had body water assessed using a bioelectrical
impedance analyzer (BIA), and body composition
assessed using a Dual-Energy X-Ray Absorptiometer
(DEXA). They also performed 1RM tests on the bench
press and hip sled/leg press and performed a 30-second
Wingate anaerobic capacity sprint test on a cycle ergom-
eter. Subjects then began a 7-day initial supplementation
phase. After 7 days, subjects repeated all tests with the
exception of 1RM strength measures. The subjects then
followed supplementation schedules for 21-days and
Table 1 Overview of Study Design
Familiarization and Entry Baseline Day 0 Loading Phase Day 7 Maintenance Phase Day 28
Familiarization session 4-Day Diet History 4-Day Diet History 4-Day Diet History
Informed Consent Form Muscle Biopsy Submit Training Log Submit Training Log
Demographic Form Fasting Blood Sample
Body Weight
Muscle Biopsy Muscle Biopsy
Health History Form Body Water (BIA) Fasting Blood Sample Fasting Blood Sample
Exercise History Form DEXA Body Composition Body Weight Body Weight
4-day Dietary History 1 RM Leg Press Body Water (BIA) Body Water (BIA)
General Exam to Determine
Qualifications to Participate
in Study
1 RM Bench Press DEXA Body Composition DEXA Body Composition
Height and Body Weight Wingate Anaerobic
Capacity Test
Wingate Anaerobic Capacity Test 1 RM Leg Press
Practice Wingate Anaerobic
Capacity Test
Loading Phase of
Supplementation Begins
Low-Dose Maintenance Phase
of Supplementation Begins
1 RM Bench Press
Randomization into one of
three groups (CrM, KA-L, KA-H)
Maintain Training Log Wingate Anaerobic Capacity Test
Instructions for Supplementation
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sessment of acute and chronic supplementation proto-
cols on muscle creatine levels, body composition,
exercise performance, as well as markers of clinical
health and safety. Participants were asked to maintain
their current training programs and record all workouts.
Participants were also asked to report side effects on a
weekly basis.
Supplementation protocol
Participants were matched into one of three groups
according to body weight, training status/experience,
and age. Subjects were then randomly assigned to one of
three groups to ingest, in a double blind manner, cap-
sules containing CrM (CreapureW AlzChem AG, Trost-
berg, Germany, Lot #108631) or KA (Kre-AlkalynW All
American Pharmaceutical, Billings, MT, USA, Lot
#1067000) at two different dosages. Supplements were
provided by the supporting sponsor in red 0.75 gram (00
sized) capsules and placed in generic single-serving
packets that were put in labeled containers for double-
blind administration on a weekly basis. Creatine content
of the capsules was independently verified by Covance
Laboratories (Madison, WI). Certificate of analysis
results are presented in Table 2. Participants in the CrMTable 2 Supplement Certificate of Analysis Results
Group Entity Weight
(g)
Fill Weight
(g)
Moisture
(%)
Creati
KA-L 0.7609 0.6375 8.2
KA-H 0.7566 0.6358 8.8
CrM 0.8171 0.6975 9.4
Samples analyzed by Covance Laboratory Inc. (Madison, WI). Sample size was eightgroups ingested 8 capsules per serving containing ap-
proximately 5 g of CrM four times daily (20 g/d) for 7-
days and once per day (5 g/d) for 21-days. A small
amount of dextrose (~60 mg per capsule) was added to
the CrM capsules to enhance flowability during encapsu-
lation. Participants in the KA creatine monohydrate
equivalent group (KA-H) ingested 8 capsules per serving
containing approximately 5 g of CrM four times daily
(20 g/d) for 7-days and once per day (5 g/d) for 21-days.
Participants assigned to ingest the manufacturers recom-
mended doses of KA (KA-L) ingested 8 capsules con-
taining a total of approximately 1.5 g of KA mixed with
3.5 g of dextrose once per day and 8 capsules containing
5 g of dextrose three times per day during the initial 7-
day loading period. Thereafter, participants in the KA-L
group ingested 8 capsules per day containing 1.5 g/d of
KA mixed with 3.5 g of dextrose for 21-days. Participants
were instructed to ingest supplements at 8:00 am,
12:00 pm, 4:00 pm, and 8:00 pm during the initial 7-day
supplementation period and at 8:00 am during the main-
tenance phase. Supplementation compliance was moni-
tored by having the subjects return empty containers of
the supplements at the end of each week. In addition,
subject’s compliance was verified by administering and
collecting weekly questionnaires. After completing thene Monohydrate
(%)
Total Creatine Monohydrate
(g/per 8 capsules)
Creatinine
(ppm)
30.6 1.56 <5,000
102.0 5.19 <5,000
92.4 5.16 <5,000
capsules.
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required supplements for the next week.
Procedures
Diet and training analysis
Participants were instructed to maintain their current
dietary habits and to keep detailed dietary records. Prior
to each testing session subjects completed a dietary rec-
ord that included 3 weekdays and 1 weekend day. Diet-
ary inventories were reviewed by a registered dietitian
and analyzed for average energy and macronutrient in-
take using the Food Processor Nutrition Analysis Soft-
ware Version 9.1.0 (ESHA Nutrition Research, Salem,
OR). Participants were also instructed to maintain their
current training regimen and record the type and num-
ber of sets and repetitions performed on training logs.
Training volume was calculated by multiplying the
amount of weight lifted times the number of repetitions
performed for each set performed. Total training volume
during the study was analyzed by summing all lifts
(upper and lower body) to determine if there were any
differences among groups.
Body composition
Body composition testing occurred on day 0, 7 and 28 of
the study. Height and weight were recorded to the near-
est 0.02 kg and 0.01 cm, respectively, using a self-
calibrating digital scale (Cardinal Detecto Scale Model
8430, Webb City, Missouri). Body composition was
determined using a Hologic Discovery W QDR series
DEXA system (Hologic Inc., Waltham, MA) equipped
with APEX software (APEX Corporation Software version
12.1, Pittsburgh, PA). Quality control calibration proce-
dures were performed on a spine phantom (Hologic-X-
CLAIBER Model DPA/QDR-1 anthropometric spine
phantom) and a density step calibration phantom prior
to each testing session. DEXA has been validated as an
accurate method for body composition assessment [40].
Mean test-retest reliability studies performed on male
athletes in our lab has yielded mean coefficients of vari-
ation for total bone mineral content and total fat free/
soft tissue mass of 0.31% to 0.45% with a mean intra-
class correlation of 0.985 [41]. Body water was estimated
using an ImpediMed DF50 bioelectrical impedance
analyzer (ImpediMed, San Diego, CA).
Blood and muscle samples
Subjects donated approximately 10 ml of fasting blood
using venipuncture techniques from an antecubital vein
in the forearm according to standard sterile procedures.
Serum blood samples were sent to Quest Diagnostics
(Houston, TX) for comprehensive metabolic panel ana-
lysis using an Olympus AAU 5400 Chemistry Immuno
Analyzer (Olympus America Inc., Center Valley, PA).Whole blood samples were analyzed for complete blood
counts with platelet differentials using an Abbott Cell
Dyn 3500 automated hematology analyzer (Abbott La-
boratories, Abbott Park, IL). Reported test to test reli-
ability of performing these assays generally range from 2
to 6% for individual assays. Samples were run in dupli-
cate to verify results if the observed values were outside
control values and/or clinical norms according to stand-
ard procedures.
Muscle biopsies were obtained using a modified Berg-
strom needle biopsy technique following standard proce-
dures [42]. Percutaneous muscle biopsies (50–70 mg)
were obtained from the middle portion of the vastus
lateralis muscle of the dominant leg at the midpoint be-
tween the patella and the greater trochanter of the femur
at a depth between 1 and 2 cm into the muscle. For the
remaining two biopsies, attempts were made to extract
tissue from approximately the same location as the ini-
tial biopsy by using the pre-biopsy scar, depth markings
on the needle, and successive incisions that were made
approximately 2 cm proximal to the former site. After
removal, adipose tissue was trimmed from the muscle
specimens which were then immediately frozen in liquid
nitrogen and then stored at −80°C for later analysis. A
total of three muscle samples were obtained (Day 0, 7, &
28). Muscle tissue samples were analyzed spectrophoto-
metrically in duplicate for creatine (Cr) using methods
developed by Harris and colleagues [7,8,43]. Briefly, ap-
proximately 50–70 mg of muscle tissue was cut and
placed in a microfuge tube, and then placed in a vacuum
centrifuge (Savant ISS110 SpeedVac Concentrator,
Thermo Scientific, Milford, MA) and centrifuged for 18–
24 hours. Connective tissue was removed from the dried
samples which were then grinded into a powder in a
porcelain plate and placed into pre-weighed microfuge
tubes. Muscle metabolites were extracted in a 0.5 M per-
chloric acid/ 1 mM EDTA solution on ice for 15 minutes,
while periodically vortexing. Samples were then centri-
fuged at 7,000 rpm for 5 minutes. The supernatant was
transferred into a pre-weighed microfuge tube and neu-
tralized with 2.1 M KHCO3/0.3 M MOPS solution. The
samples were then centrifuged again at 7,000 rpm for
5 minutes and the supernatant was removed and placed
into microfuge tubes and frozen at −80°C.
Extracts were assayed for Cr in the presence of 50 mM
imidazole buffer, pH 4.7; 5 mM magnesium chloride;
20 mM potassium chloride; 25 μM phosphoenolpyruvate;
200 μM ATP; 45 μM NADH; 1250 U/mL lactate dehydro-
genase; 2000 U/mL pyruvate kinase. The assay was carried
out in a standard fluorescence microplate reader using 10
μL of sample to 1 mL of reagent. The reactant solution
was vortexed and read using a fluorometer (Shimadzu
RFMini 150, Japan) with an excitation wavelength of
340 nm and an emission wavelength of 460 nm for
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added to 1 mL of the above buffer and stabilized using
1 mL of reagent. After 10 minutes the plate was read again
for post-reaction absorbance values. Test to test reliability
of duplicate muscle creatine assays was 0.22± 2.4%
(r = 0.90) with a coefficient of variation of 6.8. We also
assayed muscle samples for phosphocreatine (PCr) but
several values were out of normal ranges, there was large
variability in values observed, and overall PCr levels
declined over time despite creatine supplementation sug-
gesting a lack of validity in this assay. Therefore, these
data were not reported.
Performance tests
Maximal strength tests were performed using a standard
isotonic Olympic bench press and hip sled/leg press
(Nebula Fitness, Versailles, OH) according to standar-
dized procedures [44]. Hand positioning on the bench
press and foot and seat position on the hip sled/leg press
were standardized between trials. Participants followed a
standardized warm-up (10 repetitions at 50% of 1RM)
prior to beginning 1RM attempts. Rest recovery was
standardized between attempts at 2-min and participants
typically reached their 1RM within 3–5 attempts after
warming up. Participants performed the hip sled/leg
press 1RM test, rested for 4 minutes, and then began
warming up on the bench press. Bench press 1RM was
determined following similar procedures as the hip sled/
leg press 1RM test. Test-to-test reliability of performing
these tests in our lab on resistance-trained participants
have yielded low day to day mean coefficients of vari-
ation and high reliability for the bench press (1.1%,
intra-class r = 0.99) and hip sled/leg press (0.7%, intra-
class r = 0.91). Subjects rested for about 20-minutes and
then warmed up on a bicycle ergometer for 3-minutes
(70 rpm @ 1 kg resistance). Participants then performed
a 30-second Wingate sprint anaerobic capacity test on a
Lode Excalibur Sport 925900 cycle ergometer (Lode BV,
Groningen, The Netherlands) at a standardized work rate
of 7.5 J/kg/rev. The seat position was standardized be-
tween trials and the participant was asked to pedal as
fast as possible prior to application of the workload and
sprint at all-out maximal capacity during the 30-second
test. Test-to-test variability in performing repeated Win-
gate anaerobic capacity tests in our laboratory yielded
correlation coefficients of r = 0.98 ±15% for mean power.
Participants practiced the anaerobic capacity test during
the familiarization session to minimize learning effects.
Side effect assessment
Participants were given weekly questionnaires on how
well they tolerated the supplement, how well they fol-
lowed the supplement protocol, and if they experienced
any medical problems/symptoms during the study.Compliance to the supplementation protocol was moni-
tored by turning in empty weekly supplement contain-
ers, supplement logs and verbal confirmation. After
completing the compliance procedures, subjects were
given the required supplements and dosages for the fol-
lowing supplementation period.
Data analysis
Participant baseline demographic data were analyzed by
one-way Analysis of Variance (ANOVA). Study data were
analyzed by Multivariate Analysis of Variance (MAN-
OVA) with repeated measures. Overall MANOVA effects
were examined using the Wilks’ Lamda time and group x
time p-levels as well as MANOVA univariate ANOVA
group effects. Greenhouse-Geisser univariate tests of
within-subjects time and group x time effects and
between-subjects univariate group effects were reported
for each variable analyzed within the MANOVA model.
In some instances, repeated measures ANOVA was run
on variables not included in a MANOVA design with
univariate group, time, and group x time interaction
effects reported. Data were considered statistically sig-
nificant when the probability of type I error was 0.05 or
less and statistical trends were considered when the
probability of error ranged between p > 0.05 to p < 0.10. If
a significant group, treatment and/or interaction alpha
level was observed, Tukey’s least significant differences
(LSD) post-hoc analysis was performed to determine
where significance was obtained. A priori power analysis
of the design indicated that an n-size of 12 per group was
sufficiently powered to identify previously reported
changes in muscle creatine content and training adapta-
tions in responses to creatine supplementation (>0.70).
Results
Subject demographics
Forty-one participants were initially recruited for the
study, completed consent forms and participated in the
required familiarization session. Of the original 41 parti-
cipants, 36 completed the 28-day research study. Three
participants dropped out due to time constraints, one
due to an unrelated illness, and one due to apprehension
of the muscle biopsy procedure. None of the participants
dropped out of the study due to side effects related to
the study protocol. Table 3 shows the baseline demo-
graphics for the participants. Overall, participants were
20.2 ± 2 years, 181 ± 7 cm, 82.1 ± 12 kg, and 14.7 ± 5% fat
with 3.8 ± 3 years of resistance training experience. One-
way ANOVA revealed no significant differences among
groups in baseline demographic variables.
Compliance, side effects, training, and diet
Based on compliance records, all participants exhibited
100% compliance with the supplementation protocol
Table 3 Participant Demographics
Group N Age (years) Height (cm) Body Weight (kg) Body Fat (%) Training (years)
KA-L 12 19.8±1.8 180.1±8.4 83.4±13.6 17.0±4.9 3.0±2.5
KA-H 12 19.5±1.2 181.0±6.3 81.2±8.1 12.8±4.1 4.0±2.9
CrM 12 21.3±2.8 181.3±6.4 81.8±13.8 14.2±4.7 4.3±3.4
p-level 0.07 0.91 0.90 0.08 0.55
Values are means ± standard deviations.
Data were analyzed by one-way ANOVA.
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duration of the 28-day supplementation protocol. Table 4
shows the total training volumes for upper and lower
body lifts. One-way ANOVA revealed that there were no
significant differences among groups in total upper body
training volume (p = 0.89) or lower body training volume
(p = 0.55). Table 5 presents mean energy intake and
macronutrient content for each group. MANOVA
revealed no overall significant Wilks’ Lambda time
(p = 0.39) or group x time (p = 0.56) interaction effects in
absolute energy intake (kcal/d), protein intake (g/d),
carbohydrate (g/d) or fat intake (g/d). MANOVA uni-
variate analysis revealed a significant time effect suggest-
ing that energy and protein intake tended to decrease
during the study but no significant interactions were
observed among groups. Similar results were observed
when assessing energy and macronutrient intake when
expressed relative to body mass.
Muscle creatine analysis
Table 6 presents muscle free creatine content data while
Figure 1 shows changes in muscle free content. Sufficient
muscle samples were obtained to measure baseline and
subsequent creatine on 25 participants. Subjects with
missing baseline or day-28 data were not included in the
analysis. Two day-7 missing creatine values were replaced
using the last observed value method. A MANOVA was
run on muscle creatine expressed in mmol/kg DW and
changes from baseline expressed in mmol/kg DW and
percent changes from baseline. An overall MANOVA time
effect (Wilks’ Lamda p=0.002) was observed with no sig-
nificant overall MANOVA group x time interactions
(Wilks’ Lambda p=0.55). MANOVA univariate analysis
revealed significant time effects in muscle free creatineTable 4 Training Volume
Group Upper Body (kg) Lower Body (kg)
KA-L 65,006 ± 35,543 40,631 ± 20,641
KA-H 74,445 ± 42,340 32,930 ± 20,258
CrM 69,227 ± 62,251 32,665 ± 19,471
p-level 0.89 0.55
Training logs were obtained on all participants (n = 36 or 12 per group).
Values are means ± standard deviations.
Data were analyzed by one-way ANOVA.content expressed in absolute terms (p= 0.03), changes
from baseline (p= 0.03), and percent changes from base-
line (p= 0.003). No significant groups x time interactions
were observed among groups. However, while no overall
group differences were observed (p= 0.14), pairwise com-
parison between the KA-L and CrM groups revealed that
changes in muscle creatine tended to be greater in the
CrM group (KA-L −1.1 ± 4.3, CrM 11.2± 4.3 mmol/kg
DW, p=0.053 [mean±SEM]; KA-L 2.4 ± 8.5, CrM
24.6± 8.5%, p = 0.078 [mean±SEM]).
Body composition
Table 7 presents body composition results observed dur-
ing the study while Figure 2 shows the changes observed
over time in fat free mass and percent body fat. Overall
MANOVA revealed significant time effects (Wilks’
Lambda p = 0.001) with no significant group x time
interactions observed (Wilks’ Lambda p= 0.90) in body
composition variables. Bodyweight increased in all
groups over time (1.0 ± 1.9, 1.42 ± 2.5 kg, p < 0.001) with
no significant group x time interaction effects observed
among groups after 7 and 28-days, respectively, of sup-
plementation (KA-L 0.7 ± 0.83, 0.9 ± 1.6; KA-H 1.7 ± 2.9,
2.3 ± 3.7; CrM 0.6 ± 1.1, 1.1 ± 1.4 kg, p = 0.35). Fat-free
mass significantly increased over time for all groups
(0.67 ± 1.0, 0.89 ± 1.2 kg, p < 0.001) with no significant
group x time interaction effects observed among groups
(KA-L 0.42 ± 1.2, 0.37 ± 1.3; KA-H 0.96 ± 0.9, 1.2 ± 1.4;
CrM 0.6 ± 0.8, 1.1 ± 0.9 kg, p = 0.43). Body fat percent
was not significantly decreased over time for all groups
(−0.28 ± 1.0, -0.22 ± 1.4%, p = 0.41) and no significant
group x time interactions were observed among groups
(KA-L −0.04 ± 1.3, 0.15 ± 1.2; KA-H −0.28 ± 0.7,
-0.31 ± 1.6; CrM −0.53 ± 0.9, -0.50 ± 1.4%, p = 0.77). Total
body water expressed as a percentage of bodyweight sig-
nificantly decreased over time for all groups (−1.25 ± 3.7,
-2.68 ± 3.4%, p < 0.001) with no significant group x time
interaction effects observed among groups (KA-L
−0.58 ± 4.1, -1.95 ± 4.4; KA-H −2.25 ± 2.0, -3.28 ± 3.1;
CrM −0.92 ± 4.6, -2.82 ± 2.6%, p = 0.71).
Training adaptations
Table 8 shows upper and lower body 1RM strength data
observed for each group while Figure 3 shows the
Table 5 Dietary Caloric and Macronutrient Intake
Variable Group Day p-level
0 7 28
Calories (kcal/day) KA-L 2,167± 900 2,202 ± 653 1,998 ± 444 Group 0.29
KA-H 2,506± 645 2,604 ± 670 2,321 ± 677 Time 0.08
CrM 2,511± 582 2,372 ± 735 2,312 ± 394 G x T 0.81
Protein (g/d) KA-L 126.3 ± 76 126.2 ± 58 112.4 ± 46 Group 0.65
KA-H 139.4 ± 46 143.2 ± 54 132.5 ± 60 Time 0.05
CrM 127.8 ± 28 131.2 ± 40 114.1 ± 35 G x T 0.97
Carbohydrate (g/d) KA-L 219.1 ± 73 203.9 ± 79 181.7 ± 53 Group 0.53
KA-H 221.9 ± 74 216.0 ± 91 206.1 ± 86 Time 0.40
CrM 231.0 ± 72 226.1 ± 93 242.6 ± 66 G x T 0.38
Fat (g/d) KA-L 78.6 ± 38 84.7 ± 27 71.6 ± 16 Group 0.20
KA-H 99.2 ± 40 105.7 ± 47 94.5 ± 35 Time 0.19
CrM 91.3 ± 32 81.3 ± 30 83.0 ± 20 G x T 0.47
Calories KA-L 26.2 ± 10.0 26.6 ± 7.9 24.4 ± 7.2 Group 0.29
(kcal/kg/d) KA-H 31.4 ± 9.5 32.1 ± 10.5 28.3 ± 9.4 Time 0.06
CrM 31.2 ± 7.5 29.0 ± 8.8 28.4 ± 5.8 G x T 0.73
Protein KA-L 1.50 ± 0.8 1.52 ± 0.7 1.36 ± 0.6 Group 0.58
(g/kg/d) KA-H 1.75 ± 0.7 1.76 ± 0.8 1.61 ± 0.8 Time 0.04
CrM 1.59 ± 0.4 1.61 ± 46 1.41 ± 0.4 G x T 0.99
Carbohydrate KA-L 2.69 ± 1.0 2.48 ± 0.9 2.21 ± 0.7 Group 0.50
(g/kg/d) KA-H 2.75 ± 0.9 2.65 ± 1.2 2.46 ± 1.0 Time 0.24
CrM 2.87 ± 0.9 2.76 ± 1.1 2.99 ± 0.9 G x T 0.34
Fat KA-L 0.96 ± 0.4 1.02 ± 0.3 0.87 ± 0.2 Group 0.23
(g/kg/d) KA-H 1.24 ± 0.6 1.31 ± 0.7 1.16 ± 0.5 Time 0.14
CrM 1.14 ± 0.4 1.0 ± 0.4 1.01 ± 0.3 G x T 0.44
Nutritional records were analyzed on all participants (n = 36 or 12 per group). Values are means ± standard deviations. Absolute and relative nutritional data were
analyzed by MANOVA. Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels.
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http://www.jissn.com/content/9/1/43changes in 1RM bench press. There was a significant in-
crease in 1RM for bench press in all groups over time
(97.6 ± 22.3 to 101.3 ± 22.6 kg, p < 0.001) with noTable 6 Muscle Creatine Levels
Variable N Group
0
Cr (mmol/kg DW) 8 KA-L 65.8 ± 15.4
9 KA-H 57.3 ± 17.7
8 CrM 51.5 ± 12.7
Cr 8 KA-L 0.0 ± 0.0
(Δ mmol/kg DW) 9 KA-H 0.0 ± 0.0
8 CrM 0.0 ± 0.0
Cr (Δ %) 8 KA-L 0.0 ± 0.0
9 KA-H 0.0 ± 0.0
8 CrM 0.0 ± 0.0
Values are means ± standard deviations. Δ represents change from baseline values.
Cr on 25 participants. Missing day-7 data in participants with baseline and day-28 v
analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and groupsignificant group x time interactions observed among
groups in changes in bench press 1RM (KA-L 3.22 ± 1.5,
KA-H 3.3 ± 6.8, CrM 4.5 ± 3.7 kg, p = 0.73). There wasDay p-level
7 28
57.9 ± 16.1 70.5 ± 20.9 Group 0.74
58.3 ± 15.6 66.3 ± 12.6 Time 0.03
62.8 ± 25.0 73.8 ± 15.6 G x T 0.46
−8.0 ± 22.3 4.71 ± 27.0 Group 0.14
1.03 ± 12.8 9.07 ± 23.2 Time 0.03
11.3 ± 23.9 22.3 ± 21.0 G x T 0.46
−6.4 ± 37.8 13.7 ± 42.2 Group 0.20
6.2 ± 29.2 27.3 ± 49.1 Time 0.003
23.5 ± 49.0 50.4 ± 44.8 G x T 0.51
Sufficient muscle samples were obtained to measure baseline and subsequent
alues were replaced using the last observed value method (n = 2). Data were
x time (G x T) interaction p-levels are reported with univariate group p-levels.
Figure 1 Changes in muscle free creatine content from baseline.
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http://www.jissn.com/content/9/1/43no significant difference observed in hip sled/leg press
1RM over time (449.5 ± 162, 471.1 ± 167, p = 0.33) or
interactions observed among groups in changes in hip
sled/leg press 1RM (KA-L 8.7 ± 111, KA-H 68.8 ± 96,
CrM −13.3 ± 185 kg, p = 0.33) Table 9 shows results for
the anaerobic capacity test while Figure 4 presents
changes in total work observed for each group. MAN-
OVA analysis revealed an overall time effect (Wilks’
Lambda p = 0.001) with no significant overall group xTable 7 Body Composition
Marker Group
0
Body Weight (kg) KA-L 83.4 ± 13.6
KA-H 81.2 ± 8.1
CrM 81.8 ± 13.8
Fat Mass (kg) KA-L 13.5 ± 5.4
KA-H 9.7 ± 3.2
CrM 11.0 ± 5.3
Fat-Free Mass (kg) KA-L 61.3 ± 8.7
KA-H 63.5 ± 8.0
CrM 62.3 ± 9.8
Body Fat Percent (%) KA-L 17.0 ± 4.9
KA-H 12.8 ± 4.1
CrM 14.2 ± 4.7
Total Body Water (%) KA-L 37.8 ± 5.0
KA-H 37.4 ± 2.9
CrM 36.7 ± 2.7
Values are means ± standard deviations. DEXA body composition and BIA determine
composition variables were analyzed by MANOVA with repeated measures. Greenh
with univariate group p-levels.time effects (Wilks’ Lambda p = 0.47) in anaerobic cap-
acity variables. Univariate MANOVA analysis revealed
that average power (p = 0.005), peak power (p = 0.003),
and total work (p = 0.005) increased in all groups over
time with no significant group x time interactions
observed among groups. Total work performed on the
anaerobic capacity sprint test increased in all groups
over time (−69 ± 1,030, 552 ± 1,361 J, p = 0.02) with no
significant group x time effects observed among groupsDay p-level
7 28
84.1 ± 14.0 84.3 ± 13.6 Group 0.94
83.0 ± 9.7 83.5 ± 10.3 Time 0.001
82.3 ± 13.6 82.9 ± 13.0 G x T 0.35
13.7 ± 5.9 13.8 ± 5.8 Group 0.11
9.6 ± 3.1 9.6 ± 3.1 Time 0.82
10.7 ± 5.4 10.6 ± 4.4 G x T 0.73
61.7 ± 8.6 61.7 ± 8.8 Group 0.77
64.4 ± 8.0 64.7 ± 8.4 Time 0.001
63.0 ± 9.6 63.4 ± 9.9 G x T 0.43
17.0 ± 5.5 17.2 ± 5.4 Group 0.06
12.5 ± 3.8 12.5 ± 3.6 Time 0.41
13.7 ± 5.0 13.7 ± 4.2 G x T 0.77
37.2 ± 4.4 35.9 ± 3.3 Group 0.26
35.1 ± 2.6 34.1 ± 1.7 Time 0.00
35.8 ± 3.0 33.9 ± 1.5 G x T 0.71
d body water were determined on 36 participants (12 per group). Body
ouse-Geisser time and group x time (G x T) interaction p-levels are reported
Figure 2 Changes in fat free mass and body fat from baseline.
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http://www.jissn.com/content/9/1/43(KA-L −278 ± 676, 64 ± 1,216; KA-H 412 ± 1,041,
842 ± 1,369; CrM −301 ± 1,224, 775 ± 1,463 J, p = 0.32).
Clinical chemistry panels
Table 10 presents blood lipid data observed throughout
the study Overall MANOVA revealed no time (Wilks’Table 8 One Repetition Maximum Strength
Variable N Group
0
Upper Body (kg) 12 KA-L 95.3 ±
11 KA-H 98.4 ±
12 CrM 99.12 ±
Lower Body (kg) 12 KA-L 445.3 ±
12 KA-H 465.4 ±
12 CrM 439.1 ±
Values are means ± standard deviations. Data were analyzed by MANOVA with repe
p-levels are reported with univariate group p-levels.Lambda p = 0.17) or groups x time effects (Wilks’
Lambda 0.15) in blood lipids. Univariate MANOVA also
found no group x time interactions in total cholesterol
(TCHL, p = 0.10), high-density lipoprotein (HDL,
p = 0.64), the ratio of TCHL to HDL (p = 0.09), and tri-
glycerides (TRIG, p = 0.45). Some group x time effectsDay p-level
28
25.4 98.6 ± 24.7 Group 0.89
18.2 101.7 ± 17.3 Time 0.001
24.0 103.7 ± 26.1 G x T 0.73
182 454.1 ± 155 Group 0.52
117 539.0 ± 163 Time 0.35
189 425.8 ± 175 G x T 0.31
ated measures. Greenhouse-Geisser time and group x time (G x T) interaction
Figure 3 Changes in bench press 1RM strength from baseline.
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http://www.jissn.com/content/9/1/43were observed among groups in low-density lipoprotein
(LDL) levels (p = 0.005) with LDL levels significantly de-
creasing after the loading phase in the CrM group. How-
ever, values remained low and near baseline. Univariate
ANOVA revealed no significant differences among
groups in blood glucose (p = 0.67).
Table 11 shows markers of catabolism and bone status.
Overall MANOVA revealed significant time (Wilks’
Lambda p < 0.001) effects with no significant group x time
effects (Wilks’ Lambda p=0.19) in markers of catabolism.
Univariate MANOVA found no significant group x time
interactions in blood urea nitrogen (BUN, p = 0.75), BUN
to creatinine ratio (p= 0.24), aspartate aminotransferase
(AST, p= 0.68), alanine aminotransferase (ALT, p= 0.48),
total protein (p= 0.84), and total bilirubin (TBIL, p = 0.26).
Serum creatinine levels increased in all groups (p < 0.001)
over time with a significant group x time interaction dem-
onstrating higher doses of creatine in the CrM and KA-HTable 9 Wingate Anaerobic Sprint Capacity
Variable N Group
0
Mean Power (W) 12 KA-L 658 ± 136
11 KA-H 689 ± 99
12 CrM 660 ± 119
Peak Power (W) 12 KA-L 1,274 ± 259
11 KA-H 1,329 ± 285
12 CrM 1,478 ± 376
Total Work (J) 12 KA-L 19,728 ± 4,076
11 KA-H 20,681 ± 2,968
12 CrM 19,799 ± 3,564
Values are means ± standard deviations. Data were analyzed by MANOVA with repe
p-levels are reported with univariate group p-levels.groups promoting significantly greater increases in serum
creatinine (p= 0.03) than the KA-L group. However, cre-
atinine levels in the CrM and KA-H groups were only 0.1
– 0.2 mg/dL greater than the KA-L group, well within
normal values for active individuals, and of no clinical sig-
nificance. MANOVA analysis of bone related markers
found no significant time (Wilks’ Lambda p= 0.83) or
group x time effects (Wilks’ Lambda p=0.78). Likewise,
univariate MANOVA analysis revealed no significant
interactions among groups in bone mineral content
(p= 0.66), albumin (ALB, p = 0.89), globulin (GLOB,
p= 0.42), the ratio of ALB to GLOB (p= 0.45), calcium
(p= 0.76), or alkaline phosphatase (ALK, p= 0.65).
Table 12 presents serum electrolyte data. Overall MAN-
OVA analysis revealed a significant time effect (Wilks’
Lambda p=0.02) with no significant overall interaction
(Wilks’ Lambda p=0.26). Univariate MANOVA analysis
revealed some small time effects in chloride levelsDay p-level
7 28
651± 134 660± 138 Group 0.61
703± 113 717± 114 Time 0.005
652± 108 688± 105 G x T 0.21
1,393± 286 1,585± 526 Group 0.50
1,538± 389 1,616± 378 Time 0.003
1,626± 281 1,571± 409 G x T 0.48
19,450 ± 3,910 19,792 ± 4,153 Group 0.59
21,093 ± 3,387 21,523 ± 3,432 Time 0.005
19,497 ± 3,210 20,573 ± 3,128 G x T 0.22
ated measures. Greenhouse-Geisser time and group x time (G x T) interaction
Figure 4 Changes in cycling anaerobic work capacity from baseline.
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http://www.jissn.com/content/9/1/43(p= 0.008) and a trend toward an interaction in potassium
levels (p= 0.08) but the small changes observed would
have no clinical significance. Finally, Table 12 shows whole
blood markers assessed throughout the study. Overall
MANOVA revealed no significant time (Wilks’ Lambda
p=0.25) or group x time effects (Wilks’ Lambda p=0.78).
Likewise, no significant interactions were observed amongTable 10 Serum lipids and glucose
Marker N Group
0
TCHL (mg/dl) 11 KA-L 149.1 ± 25
12 KA-H 153.3 ± 26
12 CrM 156.3 ± 20
HDL (mg/dl) 11 KA-L 48.8 ± 11.3
12 KA-H 53.0 ± 16.0
12 CrM 45.6 ± 6.5
TCHL: HDL Ratio 11 KA-L 3.16 ± 0.7
12 KA-H 3.03 ± 0.6
12 CrM 3.48 ± 0.6
LDL 11 KA-L 83.4 ± 16*
(mg/dl) 12 KA-H 79.4 ± 18*
12 CrM 89.8 ± 20
TRIG (mg/dl) 11 KA-L 84.5 ± 33
12 KA-H 105.1 ± 37
12 CrM 104.1 ± 28
Glucose (mg/dl) 11 KA-L 93.0 ± 5.1
12 KA-H 91.1 ± 6.6
12 CrM 90.5 ± 9.6
Values are means ± standard deviations. Lipid data were analyzed by MANOVA with
interaction p-levels are reported with univariate group p-levels. Glucose data were
difference from baseline. * represents p < 0.05 difference from CrM.groups in white blood cell count (WBC, p= 0.45), red
blood cell count (RBC, p= 0.64), hematocrit (p= 0.65),
hemoglobin (p =0.59), mean corpuscular volume (MCV,
p=0.56), mean corpuscular hemoglobin (MCH, p= 0.44),
mean corpuscular hemoglobin concentration (MCHC,
p=0.68), red blood cell distribution width (RBCDW,
p=0.92), or platelet count (p= 0.48).Day p-level
7 28
153.0 ± 23 149.9 ± 28 Group 0.91
152.3 ± 28 157.5 ± 22 Time 0.15
147.3 ± 19 158.9 ± 21 G x T 0.10
51.0 ± 9.3 52.9 ± 11.4 Group 0.42
53.9 ± 18.4 53.6 ± 14.4 Time 0.03
47.6 ± 7.3 48.5 ± 8.4 G x T 0.64
3.09 ± 0.6 2.92 ± 0.7 Group 0.34
2.95 ± 0.5 3.04 ± 0.5 Time 0.04
3.15 ± 0.6 3.36 ± 0.7 G x T 0.09
86.5 ± 16 81.4 ± 18* Group 0.66
82.7 ± 19 83.7 ± 16* Time 0.42
81.4 ± 15† 92.5 ± 17 G x T 0.005
77.3 ± 30 78.5 ± 37 Group 0.20
78.4 ± 26 101.1 ± 27 Time 0.07
92.1 ± 30 89.6 ± 30 G x T 0.45
90.5 ± 8.2 93.6 ± 4.7 Group 0.44
92.7 ± 8.1 90.4 ± 6.9 Time 0.57
89.6 ± 5.5 88.3 ± 6.3 G x T 0.67
repeated measures. Greenhouse-Geisser time and group x time (G x T)
analyzed by repeated measures univariate ANOVA. † represents p < 0.05
Table 11 Markers of catabolism and bone status
Marker N Group Day p-level
0 7 28
BUN (mg/dl) 11 KA-L 16.0 ± 5.3 15.3 ± 4.9 15.6 ± 5.1 Group 0.89
12 KA-H 16.1 ± 3.3 16.6 ± 3.9 16.6 ± 3.6 Time 0.70
12 CrM 16.4 ± 3.2 15.7 ± 2.7 16.1 ± 4.7 G x T 0.75
Creatinine 11 KA-L 1.04 ± 0.08 1.08 ± 0.11 1.13 ± 0.10† Group 0.07
(mg/dl) 12 KA-H 1.07 ± 0.14 1.23 ± 0.18†* 1.26 ± 0.13†* Time 0.001
12 CrM 1.11 ± 0.19 1.28 ± 0.20†* 1.23 ± 0.15†* G x T 0.03
BUN:CRN Ratio 11 KA-L 15.5 ± 5.1 14.5 ± 5.6 14.1 ± 5.6 Group 0.83
12 KA-H 15.1 ± 3.4 13.7 ± 3.4 13.3 ± 3.4 Time 0.001
12 CrM 15.2 ± 3.7 12.4 ± 2.6 13.2 ± 3.8 G x T 0.24
AST (U/L) 11 KA-L 25.4 ± 9.6 26.5 ± 8.4 29.5 ± 12.9 Group 0.62
12 KA-H 27.3 ± 10.5 25.6 ± 8.3 32.0 ± 12.0 Time 0.02
12 CrM 24.9 ± 7.9 23.8 ± 7.5 26.3 ± 7.8 G x T 0.70
ALT (U/L) 11 KA-L 21.5 ± 11.2 23.5 ± 14.2 28.7 ± 19.4 Group 0.50
12 KA-H 24.1 ± 15.6 22.3 ± 12.2 27.3 ± 9.1 Time 0.05
12 CrM 21.3 ± 7.34 18.0 ± 4.2 21.3 ± 5.5 G x T 0.48
Total Protein (g/dl) 11 KA-L 7.4 ± 0.6 7.4 ± 0.4 7.4 ± 0.4 Group 0.87
12 KA-H 7.3 ± 0.3 7.3 ± 0.3 7.3 ± 0.2 Time 0.88
12 CrM 7.3 ± 0.2 7.3 ± 0.2 7.4 ± 0.3 G x T 0.84
TBIL (mg/dl) 11 KA-L 0.84 ± 0.7 0.75 ± 0.3 0.76 ± 0.3 Group 0.60
12 KA-H 0.88 ± 0.5 0.89 ± 0.5 0.77 ± 0.4 Time 0.90
12 CrM 0.63 ± 0.2 0.71 ± 0.2 0.77 ± 0.2 G x T 0.26
Bone Mineral 11 KA-L 2,517± 404 2,503 ± 409 2,505 ± 398 Group 0.59
Content (g) 12 KA-H 2,632± 457 2,604 ± 466 2,615 ± 456 Time 0.49
12 CrM 2,446± 344 2,456 ± 0.2 2,441 ± 351 G x T 0.66
Albumin (g/dl) 11 KA-L 4.80 ± 0.3 4.81 ± 0.4 4.81 ± 0.2 Group 0.95
12 KA-H 4.83 ± 0.2 4.74 ± 0.2 4.78 ± 0.1 Time 0.73
12 CrM 4.82 ± 0.2 4.80 ± 364 4.79 ± 0.2 G x T 0.89
Globulin (g/dl) 11 KA-L 2.60 ± 0.4 2.63 ± 0.3 2.55 ± 0.3 Group 0.90
12 KA-H 2.56 ± 0.3 2.58 ± 0.2 2.52 ± 0.3 Time 0.85
12 CrM 2.55 ± 0.3 2.54 ± 0.2 2.62 ± 0.3 G x T 0.42
Alb:Glob Ratio 11 KA-L 1.88 ± 0.3 1.85 ± 0.2 1.90 ± 0.2 Group 0.98
12 KA-H 1.90 ± 0.1 1.86 ± 0.2 1.91 ± 0.1 Time 0.70
12 CrM 1.88 ± 0.2 1.90 ± 0.2 1.84 ± 0.2 G x T 0.45
Calcium (mg/dl) 11 KA-L 9.87 ± 0.5 9.85 ± 0.5 9.76 ± 0.4 Group 0.42
12 KA-H 9.83 ± 0.2 9.81 ± 0.4 9.84 ± 0.2 Time 0.51
12 CrM 9.77 ± 0.3 9.63 ± 0.4 9.67 ± 0.3 G x T 0.76
ALK (U/L) 11 KA-L 82.0 ± 16.4 84.1 ± 20.5 83.9 ± 17.0 Group 0.88
12 KA-H 81.1 ± 29.7 83.8 ± 30.3 87.1 ± 27.6 Time 0.29
12 CrM 78.9 ± 20.7 80.6 ± 26.4 78.8 ± 23.1 G x T 0.65
Values are means ± standard deviations. Data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and group x time (G x T) interaction
p-levels are reported with univariate group p-levels. † represents p < 0.05 difference from baseline. * represents p < 0.05 difference from KA-L.
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The purpose of this study was to determine if supple-
menting the diet with recommended (1.5 g/d for 28-days) or creatine equivalent loading and maintenance
doses of a purported buffered form of creatine (20 g/d
for 7-days and 5 g/d for 21-days) was more effective in
Table 12 Serum electrolyte status
Marker N Group Day p-level
0 7 28
Sodium (mmol/L) 11 KA-L 140.1 ± 2.3 139.9 ± 1.1 140.0 ± 1.3 Group 0.98
12 KA-H 139.9 ± 2.3 139.7 ± 2.4 140.3 ± 2.1 Time 0.28
12 CrM 140.8 ± 2.1 139.3 ± 1.4 139.7 ± 1.6 G x T 0.57
Potassium (mmol/L) 11 KA-L 4.54 ± 0.3 4.86 ± 0.4 4.82 ± 0.3 Group 0.65
12 KA-H 4.89 ± 0.5 4.71 ± 0.6 5.00 ± 0.3 Time 0.11
12 CrM 4.74 ± 0.4 4.93 ± 0.4 4.81 ± 0.4 G x T 0.08
Chloride (mmol/L) 11 KA-L 103.3 ± 2.2 103.0 ± 2.4 103.8 ± 1.9 Group 0.21
12 KA-H 102.4 ± 2.2 101.5 ± 2.2 102.6 ± 2.4 Time 0.008
12 CrM 104.3 ± 2.2 102.3 ± 1.7 103.1 ± 1.8 G x T 0.21
Values are means ± standard deviations. Data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and group x time (G x T) interaction
p-levels are reported with univariate group p-levels.
Table 13 Whole blood markers
Marker N Group Day p-level
0 7 28
WBC (x103/ul) 9 KA-L 5.73 ± 0.6 6.13 ± 0.5 6.17 ± 1.5 Group 0.95
12 KA-H 5.83 ± 1.1 5.76 ± 0.9 6.36 ± 1.1 Time 0.16
12 CrM 5.97 ± 1.2 5.73 ± 1.0 5.98 ± 1.2 G x T 0.45
RBC (x106/ul) 9 KA-L 5.44 ± 0.4 5.38 ± 0.5 5.44 ± 0.3 Group 0.28
12 KA-H 5.10 ± 0.4 5.18 ± 0.3 5.23 ± 0.3 Time 0.91
12 CrM 5.42 ± 0.5 5.41 ± 0.5 5.35 ± 0.7 G x T 0.64
Hematocrit (%) 9 KA-L 48.4 ± 3.4 47.9 ± 4.3 48.1 ± 2.9 Group 0.17
12 KA-H 46.5 ± 3.2 47.0 ± 2.8 47.4 ± 1.8 Time 0.96
12 CrM 45.9 ± 2.3 46.1 ± 2.5 45.2 ± 5.4 G x T 0.65
Hemoglobin (g/dl) 9 KA-L 16.0 ± 1.6 16.0 ± 1.6 16.0 ± 1.2 Group 0.21
12 KA-H 15.2 ± 1.2 15.7 ± 1.0 15.6 ± 0.7 Time 0.60
12 CrM 15.1 ± 0.9 15.2 ± 1.1 14.9 ± 2.0 G x T 0.62
MCV (fL) 9 KA-L 89.0 ± 2.8 88.9 ± 2.9 88.3 ± 2.8 Group 0.10
12 KA-H 91.1 ± 3.5 90.8 ± 3.1 90.7 ± 3.6 Time 0.03
12 CrM 85.4 ± 9.2 85.7 ± 9.5 85.0 ± 9.1 G x T 0.56
MCH (pg/cell) 9 KA-L 29.4 ± 1.5 29.6 ± 1.2 29.3 ± 1.2 Group 0.34
12 KA-H 29.8 ± 1.6 30.2 ± 1.5 28.4 ± 4.9 Time 0.20
12 CrM 28.1 ± 3.5 28.3 ± 3.7 27.9 ± 3.3 G x T 0.44
MCHC(g/dl) 9 KA-L 33.0 ± 1.3 33.3 ± 0.9 33.2 ± 0.9 Group 0.73
12 KA-H 32.8 ± 0.9 33.3 ± 0.8 32.9 ± 0.6 Time 0.22
12 CrM 32.9 ± 1.1 32.9 ± 1.3 32.9 ± 0.8 G x T 0.68
RBCDW (%) 9 KA-L 13.0 ± 0.5 13.0 ± 0.9 12.9 ± 0.7 Group 0.34
12 KA-H 13.8 ± 1.1 13.7 ± 1.0 13.5 ± 1.5 Time 0.41
12 CrM 13.7 ± 1.4 13.7 ± 1.7 13.6 ± 1.6 G x T 0.92
Platelet Count (x103/ul) 9 KA-L 266 ± 45 266 ± 52 280 ± 45 Group 0.12
12 KA-H 253 ± 54 248 ± 62 269 ± 65 Time 0.32
12 CrM 222 ± 69 222 ± 74 216 ± 65 G x T 0.48
Values are means ± standard deviations. White and red cell whole blood markers were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time
and group x time (G x T) interaction p-levels are reported with univariate group p-levels.
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http://www.jissn.com/content/9/1/43increasing muscle creatine retention, body composition,
strength, and/or anaerobic capacity than supplementing
the diet with creatine monohydrate (20 g/d for 7-days
and 5 g/d for 21-days). Additionally, the study was
undertaken to determine whether supplementing the
diet with recommended or equivalent creatine doses of a
purported buffered form of creatine was associated with
fewer side effects in comparison to creatine monohy-
drate. Results of the present study clearly show that sup-
plementing the diet with a purported buffered form of
creatine is not a more efficacious and/or a safer form of
creatine to consume than creatine monohydrate.
According to product claims [28,30], KA is “up to ten
times more powerful than ordinary Creatine”. The ra-
tionale for this contention is based on experiments
reported in a patent [29] and/or on the manufacturer’s
website [28,30] which indicates that KA has less conver-
sion of creatine to creatinine in fluid over time com-
pared to creatine monohydrate. This is despite the fact
that studies show that creatine monohydrate is not sig-
nificantly degraded to creatinine during the normal di-
gestive process and nearly 99% of creatine monohydrate
that is orally ingested is either taken up by tissue or
excreted in the urine [1-3,18,21]. Because of this fact, an
accepted method of assessing whole body creatine reten-
tion has been to subtract daily urinary creatine excretion
from daily dietary intake of creatine [32,33,45-47]. Add-
itionally, while it is true that generally the lower the pH
and higher the temperature, the greater conversion of
creatine to creatinine, studies show that this process
takes several days to occur at significant levels even
when creatine is exposed to low pH environments
[1,19,48]. As described in a recent review [1], the deg-
radation of creatine can be reduced or even halted by ei-
ther lowering the pH to under 2.5 or increasing the pH.
A very high pH results in the deprotonation of the acid
group, thereby slowing down the degradation process by
making it more difficult for the intramolecular
cyclization of creatine to creatinine. However, a very low
pH (as is the case in the stomach) results in the proton-
ation of the amide function of the creatine molecule,
thereby preventing the intramolecular cyclization of cre-
atine to creatinine [1]. This is the reason that the con-
version of creatine to creatinine in the gastrointestinal
tract has been reported to be minimal regardless of tran-
sit time [7,18,20]. Thus, on the surface, the KA manufac-
turer’s claims that creatine monohydrate is degraded to
creatinine in large amounts after oral ingestion and that
a “buffered” or “pH-correct” would significantly reduce
this effect once consumed and thereby promote greater
uptake of creatine in the muscle is inconsistent with
available literature on creatine [1].
Results of the present study do not support claims that
a large amount of creatine monohydrate was convertedto creatinine during the digestive process and thereby
resulted in less of an increase in muscle creatine than
KA. In this regard, while serum creatinine levels
increased to a greater degree in the KA-H and CrM
groups that ingested larger amounts of creatine, the 0.1 -
0.2 mg/dL greater increase observed in creatinine com-
pared to the KA-L group was well within normal limits
(i.e., <1.28 ± 0.20 mg/dl) particularly for resistance-
trained males. Therefore, this small change would be
clinically insignificant. Additionally, a significant increase
from baseline in serum creatinine was also observed in
the KA-L and KA-H groups despite claims that KA
completely prevents the conversion of creatine to cre-
atinine. These findings do not support contentions that
CrM is degraded to creatinine in large amounts or that
KA is not converted to creatinine at all.
Previous research has shown that ingestion of 20 g/d
of CrM for 5–7 days can increase muscle creatine con-
tent 10-40% after 5–7 d of supplementation [1,4-8,10].
Prolonged low-dose ingestion of CrM (e.g., 2 – 3 g/d for
4–6 weeks) has also been reported to increase muscle
creatine content in a similar manner as loading strat-
egies [4,7,8]. The manufacturer of KA claims that ingest-
ing 1.5 g of KA is equivalent to ingesting 10–15 g of
CrM [28]. If this were true, those ingesting recom-
mended levels of KA (1.5 g/d for 28-days) should experi-
ence a similar increase in muscle creatine as those
participants ingesting recommended loading (20 g/d for
7-days) and maintenance doses (5 g/d for 21-days) of
CrM. Results of the present study indicated that supple-
menting the diet with manufacturer’s recommended
levels of KA (1.5 g/d) did not increase muscle free creat-
ine content to the same degree as loading and mainten-
ance doses of CrM. In fact, although no overall group
effect was observed among the three groups studied
(p = 0.14), pairwise comparison of the mean group
change from baseline in the KA-L group was 11 times
less than the change observed following CrM supple-
mentation (KA-L −1.1 ± 4.3, CrM 11.2 ± 4.3 mmol/kg DW
[mean ± SEM], p = 0.053). After 28-days of supplemen-
tation, muscle free creatine content in the KA-L group
was increased by 4.71 ± 27.0 mmol/kg DW compared to
22.3 ± 21.0 mmol/kg DW in the CrM group representing
a 4.7 fold less effect of KA supplementation than CrM
when comparing recommended levels. Consequently, re-
sults of the present study do not support claims that in-
gesting 1.5 grams of KA is as effective as ingesting 10–15
grams of creatine monohydrate. Even when participants
ingested creatine equivalent amounts of KA and CrM
(i.e., 20 g/d for 7-days and 5 g/d for 21-days), KA did
not promote greater increases in muscle free creatine.
In fact, while not significantly different, changes in mus-
cle creatine in the KA-H group were more than two
times less than the changes observed in the CrM group
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Thus, results of the present study do not support claims
that ingesting a purported buffered form of creatine is
more effective in increasing muscle creatine content than
creatine monohydrate.
While some may argue that since there is generally
large variability in measuring muscle phosphagen levels
and we were unable to obtain reliable PCr measure-
ments, it is difficult to make a definitive conclusion
about the effects of KA on muscle creatine content
based on measuring muscle free content alone. However,
present findings also provide no support for claims that
KA supplementation is “up to ten times more powerful
than ordinary Creatine.” In this regard, while time
effects were observed in training adaptations, supple-
menting the diet with KA (at recommended or creatine
equivalent loading and maintenance doses) did not pro-
mote statistically greater gains in fat free mass, 1 RM
strength, or anaerobic sprint performance capacity com-
pared to CrM. At best, one can conclude that ingesting
recommended and creatine equivalent loading and
maintenance amounts of KA resulted in similar training
adaptations as creatine monohydrate supplementation at
recommended loading and maintenance levels. However,
results of the present investigation provide no evidence
to support claims that KA is “the world’s most potent cre-
atine” [28].
Further, results of the present investigation provided
no evidence that KA is a safer form of creatine to con-
sume at either lower recommended levels or higher cre-
atine equivalent doses compared to normal loading and
maintenance doses of creatine monohydrate. In this re-
gard, there were no significant differences observed
among groups in BIA determined total body water or
serum electrolyte status. Likewise, no cramping or other
side effects were reported. These findings are consistent
with previous studies that have indicated that creatine
supplementation does not promote dehydration and/or
cramping [9,21-26]. There were also no significant dif-
ferences observed among groups in serum lipids (TCHL,
HDL, TCHL:HDL ratio, TRIG) or blood glucose. Serum
LDL decreased slightly in response to creatine loading in
the CrM group but returned to baseline after ingesting
maintenance doses of CrM suggesting these changes
were transient. Additionally, no significant differences
were observed among groups in markers of catabolism
(BUN, BUN:CRN, AST, ALT, Total Protein, TBIL), mar-
kers of bone status (bone mineral content, ALB, GLOB,
ALB:GLOB, calcium, ALK) or whole blood markers
(WBC, RBC, Hematocrit, Hemoglobin, MCV, MCH,
MCHC, RBCDW, platelet counts). Moreover, values
remained within normal levels for active individuals.
These findings are consistent with other studies that
have examined the safety of creatine supplementation inactive individuals [1,3,21,26,27,38]. Consequently, present
findings do not support claims that KA is a safer form
of creatine to ingest than creatine monohydrate.Conclusion
In summary, supplementation of the diet with recom-
mended doses of a purported buffered form of creatine
(1.5 g/d) for 28-days or equivalent loading (20 g/d for 7-
days) and maintenance doses (5 g/d for 21-days) of CrM
did not promote greater increases in muscle creatine
content or training adaptations in comparison to creat-
ine monohydrate (20 g/d for 7-days, 5 g/d for 21-days).
Additionally, there was no evidence to support claims
that the buffered form of creatine was associated with
fewer side effects or was a safer form of creatine to con-
sume than creatine monohydrate. While it could be
argued that supplementing the diet with any form of
creatine may provide some health and/or ergogenic ben-
efits over time as long as it delivers sufficient amounts
of creatine to increase muscle creatine content; present
findings do not support claims that KA is a more effica-
cious and/or safer form of creatine than creatine mono-
hydrate. With this said, some limitations of this study
should be noted. For example, this study did not have a
control group and depended on participants to self-
report side effects. Therefore, while the safety profile of
short and long-term creatine monohydrate supplementa-
tion has been well established, safety and efficacy could
only be compared to ingesting different levels and forms
of creatine and not controls. There is also variability in
conducting muscle and blood assays as well as variability
in conducting performance tests. In some instances,
large mean differences among groups were either not
statistically significant or only approached significance.
It is possible that some of these differences would have
been significant if a control group was included in the
study design and/or more subjects were studied to in-
crease statistical power. Nevertheless, results from the
present study do not support claims that KA is a more
efficacious and/or safer form of creatine to consume
than creatine monohydrate.
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